Manufacturer: Emcure Pharmaceuticals Ltd
Salt Composition : Leuprolide(22.5mg)
Vial of 1 Injection
(Inclusive of all taxes)
Advanced prostatic cancer is a cancer (abnormal cell multiplication and differentiation) that originates in the prostate gland and spreads to the other parts of the body. It is characterized by the symptoms such as painful urination, decreased urine pressure, blood in the semen, bone pain, leg swelling, and weakness.
Do not receive ELIGARD 22.5MG INJECTION if you are allergic to Leuprolide, GnRH, GnRH agonist analogs.
Before receiving this medicine, inform your doctor if you have liver impairment, kidney impairment, congenital long QT syndrome, congestive heart failure, frequent electrolyte abnormalities, metastatic vertebral lesions, urinary tract obstruction, or diabetes.
Before receiving this medicine, inform your doctor if you have a history of seizures, epilepsy, cerebrovascular disorders, or central nervous system anomalies/tumours. ELIGARD 22.5MG INJECTION is not recommended for use in pregnant women, breastfeeding women, and children.
It should be used with caution in elderly patients (aged above 65 years). Consult your doctor before receiving.
The most common side effects associated with the use of ELIGARD 22.5MG INJECTION are general pain, reactions at the site of injection, hot flashes/sweating, gastrointestinal disorders, joint disorders, shrinking of testes, urinary disorders, infections in upper respiratory tract, and fatigue. Consult your doctor if any of these side effects worsens.
